Twice-yearly asthma antibody depemokimab cut flare-ups but not day-to-day symptoms
A pooled analysis of four trials found depemokimab roughly halved exacerbations, yet it did not significantly improve asthma control or reach the threshold for a meaningful quality-of-life gain.
Depemokimab is the first asthma biologic designed to be given just twice a year, and that convenience has driven much of the enthusiasm around it. A new systematic review and meta-analysis pooling four randomised trials offers a more complete ledger: the drug clearly reduced asthma flare-ups, but it did not significantly improve patients' day-to-day symptom control and fell short of the accepted threshold for a meaningful improvement in quality of life [s1]. The analysis was an independent, prospectively registered review rather than a manufacturer report, which is part of why its mixed verdict is worth reading carefully [s1].
Depemokimab is an ultra-long-acting monoclonal antibody that blocks interleukin-5, a signalling protein that drives the eosinophil-rich inflammation behind much severe asthma. It is engineered for high binding affinity and a long half-life so that a single dose suppresses eosinophils for months, enabling the twice-yearly schedule that sets it apart from existing anti-IL-5 drugs given every four or eight weeks [s2]. Its phase 3 evidence base rests chiefly on the SWIFT-1 and SWIFT-2 trials [s2].
What the review pooled
The reviewers searched PubMed, Embase, the Cochrane databases and ClinicalTrials.gov for randomised controlled trials comparing depemokimab with placebo, and pre-registered their protocol with PROSPERO [s1]. They combined four trials enrolling 954 participants in total, and examined four outcomes: asthma control measured by the five-item Asthma Control Questionnaire (ACQ-5); the rate of asthma exacerbations; quality of life measured by the St George's Respiratory Questionnaire (SGRQ); and adverse events [s1].
Two of those outcomes are the ones patients feel most directly. ACQ-5 captures how much asthma intrudes on ordinary days — waking at night, breathlessness, reliever use. SGRQ captures the broader toll on daily life. The exacerbation rate, by contrast, counts the serious flare-ups that send people to steroids, urgent care or hospital.
What it found
On flare-ups, the result was strong and consistent. Depemokimab reduced the exacerbation rate with an incidence rate ratio of 0.47 (95% CI 0.36 to 0.59), with no measurable heterogeneity across the trials (I-squared 0%) and a highly significant p-value below 0.001 [s1]. In plain terms, the pooled estimate is roughly a halving of exacerbations, and the trials agreed with one another.
On the outcomes patients notice day to day, the picture was weaker. For asthma control, depemokimab did not significantly improve ACQ-5: the mean difference was -0.30 (95% CI -0.92 to 0.32), an interval straddling zero, with substantial disagreement between trials (I-squared 73.6%) and a non-significant p-value of 0.23 [s1]. For quality of life, depemokimab did improve SGRQ scores by a mean difference of -2.80 points (95% CI -5.38 to -0.23; p=0.033), but the reviewers note this did not reach the minimal clinically important difference — the smallest change a patient would actually perceive as better [s1]. Safety was comparable to placebo [s1].
Why the split matters
A treatment that cuts exacerbations without measurably improving symptoms or crossing the quality-of-life threshold is not a failure, but it is a narrower success than the marketing of a twice-yearly injection might imply. Preventing flare-ups is valuable on its own — exacerbations carry steroid exposure, lost work and school, and risk — and the exacerbation finding here is the most robust in the analysis [s1]. But patients weighing a new biologic often want to know whether they will feel better on ordinary days, and on that question the pooled data do not yet support a clear yes [s1].
Several caveats sit behind the numbers. Four trials totalling 954 participants is a modest evidence base, and the high heterogeneity on the ACQ-5 outcome means the trials were not measuring the same effect in the same way, which weakens any single summary figure for symptom control [s1]. A meta-analysis can only be as good as the trials it pools, and pooling a small number of studies can be sensitive to the choices each one made about who to enrol and how to measure control.
What it means
For people with severe eosinophilic asthma, depemokimab's appeal is real: fewer flare-ups on a schedule as infrequent as any biologic on the market, with a safety profile that looked like placebo in these trials [s1][s2]. The honest framing is that the convincing benefit is on exacerbations, not on the everyday symptom burden or on a quality-of-life gain large enough to feel [s1]. Anyone told that a twice-yearly shot will transform how their asthma feels day to day is being sold more than the pooled evidence currently shows. What to watch next is whether longer or larger head-to-head trials against existing anti-IL-5 drugs close, or confirm, that gap.
Sources
- [s1] Effect of depemokimab on asthma control and clinical outcomes: a systematic review and meta-analysis of randomized controlled trials. Expert Review of Respiratory Medicine, 13 June 2026. https://doi.org/10.1080/17476348.2026.2688299
- [s2] Depemokimab: toward biannual biologic therapy for severe eosinophilic asthma. Respiratory Research, 8 July 2026. https://doi.org/10.1186/s12931-026-03801-4
Sources
- Effect of depemokimab on asthma control and clinical outcomes: a systematic review and meta-analysis of randomized controlled trials — Expert Review of Respiratory Medicine , June 13, 2026
- Depemokimab: toward biannual biologic therapy for severe eosinophilic asthma — Respiratory Research , July 8, 2026
More on
Most European severe asthma patients on biologics still had active disease
A registry snapshot of 13,455 adults measures how far the biologic era has moved severe asthma toward remission, and finds the inflammation these drugs target still detectable in most patients.
Can an asthma biologic get patients off long-term steroids? Mostly, a trial finds.
35% of patients on tezepelumab stopped oral steroids entirely, versus 21% on placebo, without losing asthma control — in a drug that targets inflammation upstream of the eosinophil count doctors usually check.
Astegolimab cut COPD flare-ups in one trial but not in its twin
Two large trials of the anti-ST2 antibody gave discordant results: a modest signal in the phase 2b study, and a missed primary endpoint for the same dose in the confirmatory phase 3.
FDA approves garetosmab for fibrodysplasia ossificans progressiva
Regeneron's activin A antibody, brand name Pasatru, cleared the FDA on 19 August. In the pivotal 63-patient trial, new abnormal-bone lesions fell by 90% or more against placebo over 56 weeks.